Therapeutic Antibodies – Products

Lonza, announced the extension of a collaboration with a major biopharmaceutical partner for the commercial-scale filling of ADCs.

Extended long-term collaboration to provide significant additional bioconjugation capacity for commercialization of antibody-drug conjugates (ADCs) for use against hard-to-treat cancers.

Learn more!

This whitepaper highlights the key molecular components of ADCs and the challenges and opportunities for their future development.

For a smooth molecule journey from benchtop to clinic you need to make the most informed candidate selection and reduce the risk of failure and complications during development. Our BiacoreTM systems support informed decision-making during the lead candidate selection process. Its technology delivers valuable insights into developability such as manufacturability and safety.

Monoclonal antibody (mAb)–based therapeutics have been very successful in treating various diseases, including cancer. The manufacturing of these therapeutic antibodies is a complex operation with low levels of aggregates being a critical quality attribute of the final product, as this will impact the biological activity.

Lonza has launched the TheraPRO® CHO Media System, a new cell culture platform that simplifies processes and optimizes productivity and protein quality when used with GS-CHO cell lines.

TVM Capital Life Science, together with specialty pharma company, Tillotts Pharma has announced that the companies will jointly invest up to USD 28 million in the newly formed U.S.-based biotechnology company, Mage Biologics Inc.

RemeGen Co., Ltd announced the latest clinical research results on disitamab vedotin at this year's American Society of Clinical Oncology Annual Meeting.

GenNext Technologies, Inc., a growth-stage company that provides structural biology instrumentation, software, and services, announced today that it is collaborating with Emery Pharma.